Sharma Divyansh, Prashar Abhisheik
University of New South Wales, Sydney, NSW 2052, Australia.
Department of Cardiology, St George Hospital, Sydney, NSW 2217, Australia.
Am Heart J Plus. 2022 Jun 11;17:100150. doi: 10.1016/j.ahjo.2022.100150. eCollection 2022 May.
The role of the gut microbiome in pathophysiology, prognostication and clinical management of heart failure (HF) patients is of great clinical and research interest. Both preclinical and clinical studies have shown promising results, and the gut microbiome has been implicated in other cardiovascular conditions that are risk factors for HF. There is an increasing interest in the use of biological compounds produced as biomarkers for prognostication as well as exploration of therapeutic options targeting the various markers and pathways from the gut microbiome that are implicated in HF. However, study variations exist, and targeted research for individual putative biomarkers is necessary. There is also limited evidence pertaining to decompensated HF in particular. In this review, we synthesize current understandings around pathophysiology, prognostication and clinical management of heart failure (HF) patients, and also provide an outline of potential areas of future research and scientific advances.
肠道微生物群在心力衰竭（HF）患者的病理生理学、预后评估及临床管理中的作用具有重大的临床和研究意义。临床前和临床研究均已显示出有前景的结果，且肠道微生物群已涉及到作为HF危险因素的其他心血管疾病。人们越来越关注将所产生的生物化合物用作预后评估的生物标志物，以及探索针对肠道微生物群中与HF相关的各种标志物和途径的治疗选择。然而，研究存在差异，针对单个假定生物标志物的靶向研究很有必要。特别是关于失代偿性HF的证据也很有限。在本综述中，我们综合了目前对心力衰竭（HF）患者病理生理学、预后评估及临床管理的认识，并概述了未来研究和科学进展的潜在领域。
